First Hit	Fwd Refs	Previo	<u>us Doc</u>	Next Doc	Go to Doc#
			Gener	ate Collection	Print

L18: Entry 4 of 5 File: USPT Apr 14, 1998

US-PAT-NO: 5739008

DOCUMENT-IDENTIFIER: US 5739008 A

TITLE: DNA encoding a protein comprising calmodulin-and actin-binding human caldesmon peptide fragment

DATE-ISSUED: April 14, 1998

### INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hayashi; Ken'ichiro	Takatsuki			JP
Hashida; Takashi	Otsu			JP
Asada; Kiyozo	Shiga-ken			JP
Kotani; Hirokazu	Moriyama			JP
Kato; Ikunoshin	Uji			JP
Sobue; Kenji	Ibaraki-shi, Osaka-fu			JP

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.4, 536/23.5, 536/24.31

### CLAIMS:

#### What we claim is:

- 1. An isolated <u>DNA encoding an actin</u>- or calmodulin-binding polypeptide fragment of a human caldesmon protein, said DNA comprising a nucleotide sequence encoding at least the amino acid sequence shown in SEQ ID NO:1, wherein said caldesmon protein has the amino acid sequence shown in SEQ ID NO:5 or SEQ ID NO:6.
- 2. The DNA according to claim 1, comprising a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4.
- 3. The DNA according to claim 1, which comprises the nucleotide sequence shown in SEQ ID NO:7.
- 4. The DNA according to claim 1, which comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.
- 5. An isolated DNA which is complementary to the DNA according to any one of claims 1, 2, 3, or 4.
- 6. An isolated DNA which hybridizes under stringent conditions with the complement of the DNA according to any one of claims 1, 2, 3 or 4, said DNA coding for a human polypeptide that has calmodulin-binding activity and actin-binding activity.

- 7. An isolated DNA encoding a chimeric protein, comprising the DNA according to any one of claims 1, 2, 3, or 4.
- 8. A cDNA which codes for a human caldesmon protein having the amino acid sequence shown in SEQ ID NO:5 or SEQ ID NO:6.
- 9. The cDNA according to claim 8, which has a nucleotide sequence shown in SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 or SEQ ID NO:14.
- 10. A recombinant vector comprising the DNA according to any one of claims 1, 2, 3, 4 or 7 or the cDNA according to any one of claims 8 or 9.
- 11. A host cell transformed with the recombinant vector according to claim 10.
- 12. A process for producing a human caldesmon protein or active fragment thereof, which comprises:

culturing the host cell according to claim 11 under conditions to express the human caldesmon protein or active fragment thereof, and

isolating the caldesmon protein or active fragment.

Previous Doc Next Doc Go to Doc#

# **Refine Search**

## Search Results -

Terms	Documents
dna encoding actin	5

	US Pre-Grant Publication Full-Text Database
	US Patents Full-Text Database
	US OCR Full-Text Database
Database:	EPO Abstracts Database
	JPO Abstracts Database
	Derwent World Patents Index
	IBM Technical Disclosure Bulletins

Search:

L18				Refine Search
	Recall Text 🔷	Clear	V	Interrupt

## **Search History**

DATE: Friday, August 18, 2006 Printable Copy Create Case

Set Name Query side by side		Hit Count	Set Name result set
DB=U	DB=USPT; PLUR=YES; OP=ADJ		
<u>L18</u>	dna encoding actin	5	<u>L18</u>
<u>L17</u>	cdna encoding actin	4	<u>L17</u>
<u>L16</u>	actin with cdna	1237	<u>L16</u>
<u>L15</u>	actin with polynucleotide with encoding	7	<u>L15</u>
DB=P	$GPB, USPT, USOC, EPAB, JPAB, DWPI, TDBD; \ PLUR = YES$	; OP=ADJ	
<u>L14</u>	(L13 or 112 or 111) and 15	1	<u>L14</u>
<u>L13</u>	asada-masanori.in.	49	<u>L13</u>
<u>L12</u>	osaka-kenji.in.	37	<u>L12</u>
<u>L11</u>	osaka-kenji-irie.in.	0	<u>L11</u>
<u>L10</u>	takai-yoshimi.in.	43	<u>L10</u>
<u>L9</u>	(16 or 17 or 18) and 15	3	<u>L9</u>
<u>L8</u>	afadin	30	<u>L8</u>
<u>L7</u>	ALPHA-ACTININ-2	16	<u>L7</u>
<u>L6</u>	ALPHA-ACTININ-1	6	<u>L6</u>

<u>L5</u>	AFADIN DIL DOMAIN-BINDING PROTEIN OR ADIP	2078	<u>L5</u>
DB=U	SPT; PLUR=YES; OP=ADJ		
<u>L4</u>	L3 and (produc\$ with (polypeptide or protein))	1	<u>L4</u>
<u>L3</u>	L2 and vector	1	<u>L3</u>
<u>L2</u>	L1 and host cell	1	<u>L2</u>
<u>L1</u>	6943241.pn.	1	<u>L1</u>

END OF SEARCH HISTORY

# Freeform Search

Database:	US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database EPO Abstracts Database JPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins	
Term:	(L13 or l12 or l11) and l5	············
Display: Generate:	Documents in <u>Display Format</u> : CIT Starting with Number 1  O Hit List • Hit Count O Side by Side O Image	
	Search Clear Interrupt	
	Search History	

DATE: Friday, August 18, 2006 Printable Copy Create Case

Set Nam side by sid		Hit Count	Set Name result set
DB=P	GPB, USPT, USOC, EPAB, JPAB, DWPI, TDBD; PLUR=YES,	OP=ADJ	
<u>L14</u>	(L13 or 112 or 111) and 15	1	<u>L14</u>
<u>L13</u>	asada-masanori.in.	49	<u>L13</u>
<u>L12</u>	osaka-kenji.in.	37	<u>L12</u>
<u>L11</u>	osaka-kenji-irie.in.	0	<u>L11</u>
<u>L10</u>	takai-yoshimi.in.	43	<u>L10</u>
<u>L9</u>	(16 or 17 or 18) and 15	3	<u>L9</u>
<u>L8</u>	afadin	30	<u>L8</u>
<u>L7</u>	ALPHA-ACTININ-2	16	<u>L7</u>
<u>L6</u>	ALPHA-ACTININ-1	6	<u>L6</u>
<u>L5</u>	AFADIN DIL DOMAIN-BINDING PROTEIN OR ADIP	2078	<u>L5</u>
DB=U	SPT; PLUR=YES; OP=ADJ		
<u>L4</u>	L3 and (produc\$ with (polypeptide or protein))	1	<u>L4</u>
<u>L3</u>	L2 and vector	1	<u>L3</u>
<u>L2</u>	L1 and host cell	1	<u>L2</u>
<u>L1</u>	6943241.pn.	1	<u>L1</u>

Freeform Search Page 2 of 2

**END OF SEARCH HISTORY** 

# **Refine Search**

### Search Results -

Terms	Documents
(L13 or L12 or L11) and L5	1

Database:

US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

US Pre-Grant Publication Full-Text Database

Search:

14	
	<b>—</b>

Refine Search





Interrupt

## **Search History**

DATE: Friday, August 18, 2006 Printable Copy Create Case

Set Name Query side by side		Hit Count	Set Name result set
DB=PGPB, USPT, USOC, EPAB, JPAB, DWPI, TDBD; PLUR=YES;		OP=ADJ	
<u>L14</u>	(L13 or l12 or l11) and 15	1	<u>L14</u>
<u>L13</u>	asada-masanori.in.	49	<u>L13</u>
<u>L12</u>	osaka-kenji.in.	37	<u>L12</u>
<u>L11</u>	osaka-kenji-irie.in.	0	<u>L11</u>
<u>L10</u>	takai-yoshimi.in.	43	<u>L10</u>
<u>L9</u>	(16 or 17 or 18) and 15	3	<u>L9</u>
<u>L8</u>	afadin	30	<u>L8</u>
<u>L7</u>	ALPHA-ACTININ-2	16	<u>L7</u>
<u>L6</u>	ALPHA-ACTININ-1	6	<u>L6</u>
<u>L5</u>	AFADIN DIL DOMAIN-BINDING PROTEIN OR ADIP	2078	<u>L5</u>
DB = U	SPT; PLUR=YES; OP=ADJ		
<u>L4</u>	L3 and (produc\$ with (polypeptide or protein))	1	<u>L4</u>
<u>L3</u>	L2 and vector	1	<u>L3</u>
<u>L2</u>	L1 and host cell	1	<u>L2</u>

WEST Refine Search Page 2 of 2

<u>L1</u> 6943241.pn.

1 <u>L1</u>

END OF SEARCH HISTORY

FILE 'MEDLINE' ENTERED AT 07:04:51 ON 18 AUG 2006 FILE 'JAPIO' ENTERED AT 07:04:51 ON 18 AUG 2006 COPYRIGHT (C) 2006 Japanese Patent Office (JPO) - JAPIO FILE 'BIOSIS' ENTERED AT 07:04:51 ON 18 AUG 2006 Copyright (c) 2006 The Thomson Corporation FILE 'SCISEARCH' ENTERED AT 07:04:51 ON 18 AUG 2006 Copyright (c) 2006 The Thomson Corporation FILE 'WPIDS' ENTERED AT 07:04:51 ON 18 AUG 2006 COPYRIGHT (C) 2006 THE THOMSON CORPORATION FILE 'CAPLUS' ENTERED AT 07:04:51 ON 18 AUG 2006 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS) FILE 'EMBASE' ENTERED AT 07:04:51 ON 18 AUG 2006 Copyright (c) 2006 Elsevier B.V. All rights reserved. => s afadin dil domain-binding protein or adip# 900 AFADIN DIL DOMAIN-BINDING PROTEIN OR ADIP# => s l1 and (alpha-actinin-1 or alpha-actinin-2 or actinin# or afadin#) 5 FILES SEARCHED... 19 L1 AND (ALPHA-ACTININ-1 OR ALPHA-ACTININ-2 OR ACTININ# OR AFADIN #) => dup rem 12 PROCESSING COMPLETED FOR L2 5 DUP REM L2 (14 DUPLICATES REMOVED) => d ibib abs 13 1-5 ANSWER 1 OF 5 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN DUPLICATE 1 ACCESSION NUMBER: 2004-404616 [38] WPIDS DOC. NO. NON-CPI: N2004-322275 DOC. NO. CPI: C2004-152052 TITLE: New polynucleotide encoding an \*\*\*afadin\*\*\* dilution domain binding protein having avidity with \*\*\*afadin\*\*\* \*\*\*actinin\*\*\* , useful for diagnosing heart diseases e.g. myocardial infarction. DERWENT CLASS: B04 D16 S03 INVENTOR(S): ASADA, M; IRIE, K; TAKAI, Y (EISA) EISAI CO LTD; (ASAD-I) ASADA M; (IRIE-I) IRIE K; PATENT ASSIGNEE(S): (TAKA-I) TAKAI Y COUNTRY COUNT: PATENT INFORMATION: PATENT NO KIND DATE WEEK LA PG JP 2004135658 A 20040513 (200438)\* 37 US 2006160092 A1 20060720 (200648) APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 2004135658	• •	JP 2003-293554	20030814
US 2006160092	A1	US 2003-644084	20030820

PRIORITY APPLN. INFO: JP 2002-284263 20020927

AN 2004-404616 [38] WPIDS

AB JP2004135658 A UPAB: 20040616

NOVELTY - A polynucleotide (I) encoding an \*\*\*afadin\*\*\* dilution domain binding protein having avidity with \*\*\*afadin\*\*\* /

\*\*\*actinin\*\*\* , comprises a sequence (S1) of 2692 or 3195 nucleotides,

given in specification or a sequence which hybridizes with (S1), or encodes a protein having a sequence (S2) of 615 or 613 amino acids, given in specification or a sequence which has alterations in amino acid(s) of (S2), is new.

DETAILED DESCRIPTION - A polynucleotide (I) encoding \*\*\*afadin\*\*\* dilution domain binding protein ( \*\*\*ADIP\*\*\* ) having avidity with \*\*\*afadin\*\*\* or \*\*\*actinin\*\*\* , comprises a fully defined sequence (S1) of 2692 or 3195 nucleotides as given in the specification or a sequence which hybridizes under stringent conditions with (S1), or encodes protein having a fully defined sequence (S2) of 615 or 613 amino acids as given in the specification or a sequence which has substitution, deletion, insertion and/or addition in one or more amino acid(s) of (S2).

INDEPENDENT CLAIMS are included for the following:

- a polypeptide (II) encoded by (I);
- (2) a vector (III) comprising (I);
- (3) a host cell (IV) comprising (I) or (III);
- (4) a polynucleotide having at least 15 nucleotides, hybridizes specifically under stringent condition with (I);
- (5) a polynucleotide or the antisense polynucleotide with respect to one part of (I); and
  - (6) an antibody binding with (II).

ACTIVITY - Cardiant.

MECHANISM OF ACTION - \*\*\*Afadin\*\*\* binding inhibitor;

\*\*\*Actinin\*\*\* binding inhibitor.

USE - (I) or (II) is useful for diagnosing heart disease such as myocardial infarction or myocarditis which involves (a) detecting the expression level of (I) that encodes (II) in a subject, (b) preparing a RNA sample from the cardiac myocyte of a subject, measuring the quantity of RNA contained in RNA sample, and comparing the quantity of the measured RNA with a control, or (c) preparing a protein sample from the cardiac myocyte of a subject, measuring the quantity of (II) contained in the protein sample, and comparing the quantity of the measured polypeptide with a control. (II) is useful for the screening a candidate compound as the medical agent for controlling an actin structure which involves  $\hbox{***actinin***}$  , (II) and the test \*\*\*afadin\*\*\* or \*\*\*afadin\*\*\* compound, measuring the avidity of or an and (II), and selecting the compound to which the avidity is changed by comparing it with the control, where a test compound is not made to contact. (IV) is useful for producing (II) which involves culturing (IV), and collecting the produced (II) from the host cell or its culture supernatant (all claimed). (II) is useful for screening a therapeutic agent for treating heart disease.

ADVANTAGE - (I) is efficient in diagnosing heart disease and screening a candidate compound as medical agent for treating heart disease. Dwg.0/10

J -, --

L3 ANSWER 2 OF 5 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 2004425875 MEDLINE <<LOGINID::20060818>>

DOCUMENT NUMBER: PubMed ID: 15330861

TITLE: Requirement of the actin cytoskeleton for the association

of nectins with other cell adhesion molecules at adherens

and tight junctions in MDCK cells.

AUTHOR: Yamada Akio; Irie Kenji; Fukuhara Atsunori; Ooshio Takako;

Takai Yoshimi

CORPORATE SOURCE: Department of Molecular Biology and Biochemistry, Osaka

University Graduate School of Medicine/Faculty of Medicine,

Suita 565-0871, Japan.

SOURCE: Genes to cells : devoted to molecular & cellular

mechanisms, (2004 Sep) Vol. 9, No. 9, pp. 843-55.

Journal code: 9607379. ISSN: 1356-9597.

PUB. COUNTRY: England: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200410

ENTRY DATE: Entered STN: 28 Aug 2004

Last Updated on STN: 19 Oct 2004 Entered Medline: 18 Oct 2004

AB Nectins, Ca(2+)-independent immunoglobulin-like cell adhesion molecules (CAMs), first form cell-cell adhesion where cadherins are recruited, forming adherens junctions (AJs) in epithelial cells and fibroblasts. In

addition, nectins recruit claudins, occludin, and junctional adhesion molecules (JAMs) to the apical side of AJs, forming tight junctions (TJs) in epithelial cells. Nectins are associated with these CAMs through peripheral membrane proteins (PMPs), many of which are actin filament-binding proteins. We examined here the roles of the actin cytoskeleton in the association of nectins with other CAMs in MDCK cells stably expressing exogenous nectin-1. The nectin-1-based cell-cell adhesion was formed and maintained irrespective of the presence and absence of the actin filament-disrupting agents, such as cytochalasin D and latrunculin A. In the presence of these agents, only \*\*\*afadin\*\*\* remained at the nectin-1-based cell-cell adhesion sites, whereas E-cadherin and other PMPs at AJs, alpha-catenin, beta-catenin, vinculin, alpha- \*\*\*actinin\*\*\* , \*\*\*ADIP\*\*\* , and LMO7, were not concentrated there. The CAMs at TJs, claudin-1, occludin and JAM-1, or the PMPs at TJs, ZO-1 and MAGI-1, were not concentrated there, either. These results indicate that the actin cytoskeleton is required for the association of the nectin- \*\*\*afadin\*\*\* unit with other CAMs and PMPs at AJs and TJs.

L3 ANSWER 3 OF 5 MEDLINE on STN DUPLICATE 3 ACCESSION NUMBER: 2004451971 MEDLINE <<LOGINID::20060818>>

DOCUMENT NUMBER: PubMed ID: 15358183

TITLE: \*\*\*Afadin\*\*\* - and alpha- \*\*\*actinin\*\*\* -binding

protein \*\*\*ADIP\*\*\* directly binds beta'-COP, a subunit

of the coatomer complex.

AUTHOR: Asada Masanori; Irie Kenji; Yamada Akio; Takai Yoshimi CORPORATE SOURCE: Department of Molecular Biology and Biochemistry, Osaka

University Graduate School of Medicine/Faculty of Medicine,

Suita 565-0871, Japan.

SOURCE: Biochemical and biophysical research communications, (2004

Aug 20) Vol. 321, No. 2, pp. 350-4. Journal code: 0372516. ISSN: 0006-291X.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200410

ENTRY DATE: Entered STN: 14 Sep 2004

Last Updated on STN: 7 Oct 2004 Entered Medline: 6 Oct 2004

AB \*\*\*Afadin\*\*\* DIL domain-interacting protein ( \*\*\*ADIP\*\*\* ) is a novel protein that binds both \*\*\*afadin\*\*\* and alpha- \*\*\*actinin\*\*\* and localizes at adherens junctions, which are formed by nectins and cadherins, cell-cell adhesion molecules. \*\*\*Afadin\*\*\* is an actin filament (F-actin)-binding protein which connects nectins to the actin cytoskeleton. alpha- \*\*\*Actinin\*\*\* is another F-actin-binding protein that is indirectly associated with cadherins through the catenin complex. \*\*\*ADIP\*\*\* is at least partly involved in the physical association of

nectins and cadherins. We show here that \*\*\*ADIP\*\*\* furthermore binds beta'-COP, a subunit of the coatomer complex. \*\*\*ADIP\*\*\* co-localizes with beta'-COP at the Golgi complex in Madin Darby canine kidney and normal rat kidney cells. These results suggest that \*\*\*ADIP\*\*\* is involved in vesicle trafficking from the Golgi to the endoplasmic reticulum and through the Golgi complex by interacting with the coatomer complex.

L3 ANSWER 4 OF 5 MEDLINE on STN DUPLICATE 4
ACCESSION NUMBER: 2003053398 MEDLINE <<LOGINID::20060818>>

DOCUMENT NUMBER: PubMed ID: 12446711

TITLE: \*\*\*ADIP\*\*\* , a novel \*\*\*Afadin\*\*\* - and alpha-

\*\*\*actinin\*\*\* -binding protein localized at cell-cell

adherens junctions.

AUTHOR: Asada Masanori; Irie Kenji; Morimoto Koji; Yamada Akio;

Ikeda Wataru; Takeuchi Masakazu; Takai Yoshimi

CORPORATE SOURCE: Department of Molecular Biology and Biochemistry, Osaka

University Graduate School of Medicine/ Faculty of

Medicine, Suita 565-0871, Japan.

SOURCE: The Journal of biological chemistry, (2003 Feb 7) Vol. 278,

No. 6, pp. 4103-11. Electronic Publication: 2002-11-21.

Journal code: 2985121R. ISSN: 0021-9258.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

OTHER SOURCE: GENBANK-AF532969; GENBANK-AF532970

ENTRY MONTH: 200303

ENTRY DATE: Entered STN: 4 Feb 2003

Last Updated on STN: 22 Mar 2003 Entered Medline: 21 Mar 2003

AB \*\*\*Afadin\*\*\* is an actin filament (F-actin)-binding protein that is associated with the cytoplasmic tail of nectin, a Ca(2+)-independent immunoglobulin-like cell-cell adhesion molecule. Nectin and

strictly localize at cell-cell adherens junctions (AJs) \*\*\*afadin\*\*\* undercoated with F-actin bundles and are involved in the formation of AJs in cooperation with E-cadherin in epithelial cells. In epithelial cells \*\*\*afadin\*\*\* (-/-) mice and (-/-) embryoid bodies, the proper organization of AJs is markedly impaired. However, the molecular mechanism of how the nectin- \*\*\*afadin\*\*\* system is associated with the E-cadherin-catenin system or functions in the formation of AJs has not yet been fully understood. Here we identified a novel \*\*\*afadin\*\*\* -binding protein, named \*\*\*ADIP\*\*\* ( \*\*\*afadin\*\*\* DIL \*\*\*ADIP\*\*\* consists of 615 amino acids domain-interacting protein). with a calculated M(r) of 70,954 and has three coiled-coil domains. Northern and Western blot analyses in mouse tissues indicated that \*\*\*ADIP\*\*\* was widely distributed. Immunofluorescence and immunoelectron microscopy revealed that \*\*\*ADIP\*\*\* strictly localized at cell-cell AJs undercoated with F-actin bundles in small intestine

at cell-cell AJs undercoated with F-actin bundles in small intestine absorptive epithelial cells. This localization pattern was the same as those of \*\*\*afadin\*\*\* and nectin. \*\*\*ADIP\*\*\* was undetectable at cell-matrix AJs. \*\*\*ADIP\*\*\* furthermore bound alpha- \*\*\*actinin\*\*\*, an F-actin-bundling protein known to be indirectly associated with E-cadherin through its direct binding to alpha-catenin. These results indicate that \*\*\*ADIP\*\*\* is an \*\*\*afadin\*\*\* - and alpha-

\*\*\*actinin\*\*\* -binding protein that localizes at cell-cell AJs and may have two functions. \*\*\*ADIP\*\*\* may connect the nectin- \*\*\*afadin\*\*\* and E-cadherin-catenin systems through alpha- \*\*\*actinin\*\*\*, and \*\*\*ADIP\*\*\* may be involved in organization of the actin cytoskeleton at AJs through \*\*\*afadin\*\*\* and alpha- \*\*\*actinin\*\*\*.

L3 ANSWER 5 OF 5 JAPIO (C) 2006 JPO on STN

ACCESSION NUMBER: 2004-135658 JAPIO <<LOGINID::20060818>> TITLE: \*\*\*ADIP\*\*\* PROTEIN AND USE OF THE SAME INVENTOR: TAKAI YOSHIMI; IRIE KENJI; ASADA SHIGENORI

PATENT ASSIGNEE(S): EISAI CO LTD

PATENT INFORMATION:

#### APPLICATION INFORMATION

AN

STN FORMAT: JP 2003-293554 20030814 ORIGINAL: JP2003293554 Heisei PRIORITY APPLN. INFO.: JP 2002-284263 20020927

SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined

Applications, Vol. 2004

AB PROBLEM TO BE SOLVED: To provide a new \*\*\*afadin\*\*\* \*\*\*DIL\*\*\*

\*\*\*domain\*\*\* - \*\*\*binding\*\*\* \*\*\*protein\*\*\* ( \*\*\*ADIP\*\*\* ) gene

and a use of the new \*\*\*ADIP\*\*\* protein.

SOLUTION: This new \*\*\*afadin\*\*\* -binding protein ( \*\*\*ADIP\*\*\* ) is successfully identified by performing an yeast two hybrid screening in order to obtain an insight in how a nectin and \*\*\*afadin\*\*\* system organizes a tight junction and an adherence junction in an intercellular junction. The new protein is useful for the evaluation of a medicine for controlling the actin skeleton.

COPYRIGHT: (C) 2004, JPO

```
FILE 'MEDLINE' ENTERED AT 06:41:37 ON 18 AUG 2006
FILE 'JAPIO' ENTERED AT 06:41:37 ON 18 AUG 2006
COPYRIGHT (C) 2006 Japanese Patent Office (JPO) - JAPIO
FILE 'BIOSIS' ENTERED AT 06:41:37 ON 18 AUG 2006
Copyright (c) 2006 The Thomson Corporation
FILE 'SCISEARCH' ENTERED AT 06:41:37 ON 18 AUG 2006
Copyright (c) 2006 The Thomson Corporation
FILE 'WPIDS' ENTERED AT 06:41:37 ON 18 AUG 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION
FILE 'CAPLUS' ENTERED AT 06:41:37 ON 18 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'EMBASE' ENTERED AT 06:41:37 ON 18 AUG 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.
=> normalization and subtraction of cap-trapper
   4 FILES SEARCHED...
             5 NORMALIZATION AND SUBTRACTION OF CAP-TRAPPER
=> dupr em 11
MISSING OPERATOR EM L1
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.
=> dupr rem l1
MISSING OPERATOR REM L1
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.
=> dup rem l1
PROCESSING COMPLETED FOR L1
              1 DUP REM L1 (4 DUPLICATES REMOVED)
=> d ibib abs
     ANSWER 1 OF 1
                       MEDLINE on STN
                                                        DUPLICATE 1
                    2001084108 MEDLINE <<LOGINID::20060818>>
ACCESSION NUMBER:
DOCUMENT NUMBER:
                    PubMed ID: 11042159
TITLE:
                      ***Normalization***
                                            and
                                                  ***subtraction***
                                   ***cap*** - ***trapper*** -selected cDNAs
                    to prepare full-length cDNA libraries for rapid discovery
                    of new genes.
AUTHOR:
                    Carninci P; Shibata Y; Hayatsu N; Sugahara Y; Shibata K;
                    Itoh M; Konno H; Okazaki Y; Muramatsu M; Hayashizaki Y
CORPORATE SOURCE:
                    Laboratory for Genome Exploration Research Group, RIKEN
                    Genomic Sciences Center, Tsukuba, Japan..
                    rgscerg@rtc.riken.go.jp
SOURCE:
                    Genome research, (2000 Oct) Vol. 10, No. 10, pp. 1617-30.
                    Journal code: 9518021. ISSN: 1088-9051.
PUB. COUNTRY:
                    United States
DOCUMENT TYPE:
                    Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:
                    English
FILE SEGMENT:
                    Priority Journals
ENTRY MONTH:
                    200101
ENTRY DATE:
                    Entered STN: 22 Mar 2001
                    Last Updated on STN: 22 Mar 2001
                    Entered Medline: 18 Jan 2001
AΒ
     In the effort to prepare the mouse full-length cDNA encyclopedia, we
     previously developed several techniques to prepare and select full-length
     cDNAs. To increase the number of different cDNAs, we introduce here a
     strategy to prepare normalized and subtracted cDNA libraries in a single
     step. The method is based on hybridization of the first-strand,
     full-length cDNA with several RNA drivers, including starting mRNA as the
     normalizing driver and run-off transcripts from minilibraries containing
```

highly expressed genes, rearrayed clones, and previously sequenced cDNAs as subtracting drivers. Our method keeps the proportion of full-length cDNAs in the subtracted/normalized library high. Moreover, our method dramatically enhances the discovery of new genes as compared to results obtained by using standard, full-length cDNA libraries. This procedure can be extended to the preparation of full-length cDNA encyclopedias from other organisms.

```
=> FIL STNGUIDE
COST IN U.S. DOLLARS
                                                   SINCE FILE
                                                                    TOTAL
                                                        ENTRY
                                                                  SESSION
FULL ESTIMATED COST
                                                         19.26
                                                                   19.47
FILE 'STNGUIDE' ENTERED AT 06:43:30 ON 18 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 11, 2006 (20060811/UP).
=> s afadin dil domainbinding protein#
             0 AFADIN
             0 DIL
             0 DOMAINBINDING
             5 PROTEIN#
L3
             O AFADIN DIL DOMAINBINDING PROTEIN#
                  (AFADIN (W) DIL (W) DOMAINBINDING (W) PROTEIN#)
=> s afadin dil domain binding protein#
             0 AFADIN
             0 DIL
             0 DOMAIN
             1 BINDING
             5 PROTEIN#
             O AFADIN DIL DOMAIN BINDING PROTEIN#
                  (AFADIN (W) DIL (W) DOMAIN (W) BINDING (W) PROTEIN#)
=> s afadin dil domain-binding protein#
             0 AFADIN
             0 DIL
             0 DOMAIN
             1 BINDING
             5 PROTEIN#
L5
             O AFADIN DIL DOMAIN-BINDING PROTEIN#
                  (AFADIN (W) DIL (W) DOMAIN (W) BINDING (W) PROTEIN#)
=> s adip
             0 ADIP
L<sub>6</sub>
             0 ADIP
=> s actin#binding protein#
'#' TRUNCATION SYMBOL NOT VALID WITHIN 'ACTIN#BINDING'
The truncation symbol # may be used only at the end of a search term.
To specify a variable character within a word use '!', e.g., 'wom!n'
to search for both 'woman' and 'women'. Enter "HELP TRUNCATION" at an
arrow prompt (=>) for more information.
=> s actin# binding protein#
             0 ACTIN#
             1 BINDING
             5 PROTEIN#
L7
             0 ACTIN# BINDING PROTEIN#
                  (ACTIN# (W) BINDING (W) PROTEIN#)
=> s actin# and binding protein#
             0 ACTIN#
             1 BINDING
             5 PROTEIN#
```

0 BINDING PROTEIN#

(BINDING (W) PROTEIN#)

```
L8
             O ACTIN# AND BINDING PROTEIN#
=> s (actin# and binding) and (protein# or polypeptide#)
             0 ACTIN#
             1 BINDING
             5 PROTEIN#
             0 POLYPEPTIDE#
             0 (ACTIN# AND BINDING) AND (PROTEIN# OR POLYPEPTIDE#)
L9
=> s (actinin# and binding) and (protein# or polypeptide#)
             0 ACTININ#
             1 BINDING
             5 PROTEIN#
             0 POLYPEPTIDE#
             0 (ACTININ# AND BINDING) AND (PROTEIN# OR POLYPEPTIDE#)
L10
=> s actinin#
             0 ACTININ#
L11
=> s actin
             0 ACTIN
```

L12

0 ACTIN